SuperworthCryoport profit margin CYRX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- −20.1%
- Operating margin, 12 months
- −21.2%
- Net margin on a year earlier
- −67.6 pts
- Peer median
- 22.5%
Over the twelve months to Jun 30, 2026, Cryoport kept −20.1% of its revenue as net profit, with an operating margin of −21.2% and a gross margin of 47.1%.
Five years earlier its net margin was −18.9%.
The median for 10 large drugmakers of a similar size is 22.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 44.4% | −20.9% | 47.1% |
| FY2024 | −73.2% | −77.6% | 44.4% |
| FY2023 | −42.7% | −49.4% | 42.6% |
| FY2022 | −15.7% | −13.4% | 43.8% |
| FY2021 | n/a | −8.0% | 43.4% |
| FY2020 | −41.5% | −38.1% | 46.2% |
| FY2019 | −54.0% | −52.1% | 51.1% |
| FY2018 | −48.7% | −44.0% | 52.2% |
| FY2017 | −66.1% | −66.0% | 49.9% |
| FY2016 | n/a | n/a | 32.1% |
| FY2016 | n/a | n/a | 40.4% |
| FY2015 | n/a | n/a | 29.7% |
| FY2014 | n/a | n/a | 16.4% |
| FY2013 | n/a | n/a | −44.4% |
| FY2012 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −20.1% | −67.6 pts | −21.2% | |
| Q1 FY26 | 43.6% | +110.8 pts | −21.4% | |
| Q4 FY25 | 44.4% | +117.6 pts | −20.9% | |
| Q3 FY25 | 41.4% | +133.2 pts | −23.0% | |
| Q2 FY25 | 47.5% | +138.1 pts | −25.8% | |
| Q1 FY25 | −67.2% | −12.8 pts | −69.4% | |
| Q4 FY24 | −73.2% | −30.5 pts | −77.6% | |
| Q3 FY24 | −91.8% | −72.1 pts | n/a | |
| Q2 FY24 | −90.6% | −74.5 pts | −95.7% | |
| Q1 FY24 | −54.4% | −42.4 pts | −59.0% | |
| Q4 FY23 | −42.7% | −27.0 pts | −49.4% | |
| Q3 FY23 | −19.7% | n/a | −23.8% |
Against its peers
Companies in Drug Manufacturers - General nearest Cryoport's size, closest first, today.
| Company | Profit margin |
|---|---|
| CYRXCryoport | −20.1% |
| ABUSArbutus Biopharma | 84.2% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| COLLCollegium Pharmaceutical | 5.9% |
| OMEROmeros | n/m |
| CRMDCorMedix | 40.5% |
| ZVRAZevra Therapeutics | 42.8% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| PBYIPuma Biotechnology | 11.6% |
| Peer median | 22.5% |
Where Cryoport ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Cryoport
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.